Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages

AIDS Research and Human Retroviruses

Volumn 13, Issue 10, 1997, Pages 875-880

  Javan, Caroline M ^a   Gooderham, Nigel J ^a   Edwards, Robert J ^a   Davies, Donald S ^a   Shaunak, Sunil ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRIN; DEXTRIN 2 SULFATE; DEXTRIN 2,3,6 SULFATE; DEXTRIN 3 SULFATE; DEXTRIN 6 SULFATE; POLYSACCHARIDE SULFATE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; MACROPHAGE; MONONUCLEAR CELL; PRIORITY JOURNAL; SULFATION; SYNCYTIUM; VIRUS ISOLATION; VIRUS TRANSMISSION;

EID: 0030979349     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.875     Document Type: Article

References (24)

1. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, and Broder S: Dextran sulphate suppression of viruses in the HIV family: Inhibition of virion binding to CD4+ cells. Science 1988;240:646-649.
2. Baba M, Snoeck R, Pauwels R, and De Clercq E: Sulphated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, CMV, VSV and HIV. Antimicrob Agents Chemother 1988;32:1742-1745.
3. Hosaya M, Balzarini J, Shigeta S, and De Clercq E: Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob Agents Chemother 1991;35: 2515-2520.
4. Andrei G and De Clercq E: Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res 1990;14:287-300.
5. Lederman S, Gulick R, and Chess L: Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J Immunol 1989;143:1149-1154.
6. Schols D, Baba M, Pauwels R, Desmyter J, and De Clercq E: Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor. Proc Natl Acad Sci USA 1989;86:3322-3326.
7. Schols D, Pauwels R, Desmyter J, and De Clercq E: Dextran sulphate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 1990;175:555-561.
8. Parish CR, Low L, Warren HS, and Cunningham AL: A polyanion binding site on the CD4 molecule. J Immunol 1990;145: 1188-1195.
9. Callahan LN, Phelan M, Mallinson M, and Norcross MA: Dextran sulphate blocks antibody binding to the principal neutralising domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 1991;65:1543-1550.
10. Callahan L: HIV-1 virion-cell interactions: An electrostatic model of pathogenicity and syncytium formation. AIDS 1994;10:231-233.
11. Meylan PRA, Kornbluth RS, Zbinden I, and Richman DD: Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of HIV-1 to polyanion compounds. Antimicrob Agents Chemother 1994;38:2910-2916.
12. Shaunak S, Gooderham NJ, Edwards RJ, Payvandi N, Javan CM, Baggett N, MacDermot J, Weber J, and Davies DS: Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br J Pharmacol 1994;113:151-158.
13. Beddows S, Bieniasz P, Shaunak S, and Weber JN: HIV replication in CD4-negative cell lines: Effect of cloning, CD4 expression and inhibition by dextrin 2-sulphate. Antiviral Chem Chemother 1993;4:173-177.
14. Watson K, Edwards RJ, Shaunak S, Parmelee DC, Sarraf C, Gooderham NJ, and Davies DS: Extra-nuclear location of histones in activated human peripheral blood lymphocytes and cultured T-cells. Biochem Pharmacol 1995;50:299-309.
15. Shaunak S: Cell Surface Receptors for HIV. Ph.D. thesis, University of London, London, 1993.
16. Hollinger FB, Bremer JW, Myers LE, Gold JW, and McQuay L: Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-1794.
17. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black FU, Reichelderfer PS, D'Aquila RT, et al.: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-1101.
18. De-Wolf F, Hogervorst E, Goudsmit J, Fenyö EM, Rubsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempala SD, et al.: Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: Phenotypic and genotypic characteristics. AIDS Res Hum Retroviruses 1994;10:1387-1400.
19. Schacker T, Coombs RW, Collier AC, Zeh JE, Fox I, Alam J, Nelson K, Eggert E, and Corey L: The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1. J Infect Dis 1994;169:37-40.
20. McClure MO, Whitby D, Patience C, Gooderham NJ, Bradshaw A, Cheingsong-Popov R, Weber JN, Davies DS, Cook GMW, Keynes RJ, and Weiss RA: Dextrin sulphate and fucoidan are potent inhibitors of HIV infection in vitro. Antiviral Chem Chemother 1991;2:149-156.
21. Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, Hascall VC, and Norcoss MA: Cell surface heparan sulfate proteoglycan mediates HIV-1 infection in T-cell lines. AIDS Res Hum Retroviruses 1993;9:167-174.
22. Fouchier RAM, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, and Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66: 3183-3187.
23. Okada T and Gurney ME: Single basic amino acid substitutions at position 302 or 320 in the V3 domain of the HIV type 1 are not sufficient to alter the antiviral activity of dextran sulphate and heparin. AIDS 1995;11:571-575.
24. Morgan JR, Le Doux JM, Snow RG, Tompkins RG, and Yarmush ML: Retrovirus infection: Effect of time and target cell number. J Virol 1995;69:6994-7000.